Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine + tislelizumab + lenvatinib as neoadjuvant/adjuvant therapy for high‑risk intrahepatic cholangiocarcinoma
ChiCTR2300078068Phase 2Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, tislelizumab and lenvatinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: 1-year recurrence-free survival rate. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
capecitabinetislelizumablenvatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2300078068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078068.